Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind dose-finding trial of inhaled HK241 in adults with bronchiectasis and pulmonary Pseudomonas aeruginosa infection
CTR20253328Phase 2Active
- Sponsor
- Nanjing Huagai Pharmaceutical
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in bronchiectasis and Pseudomonas aeruginosa pulmonary infection comparing HK241 nebulized inhalation solution with HK241 matching placebo simulator (2 arms). Primary endpoint: Change from baseline in sputum Pseudomonas aeruginosa burden. Started Jan 2026; status: active.
02
Drugs
amikacin
03
Conditions
bronchiectasisPseudomonas aeruginosa pulmonary infection
Beyond the preview
Go deeper on CTR20253328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253328.